Orencia approved for polyarticular juvenile idiopathic arthritis

Orencia (abatacept) is now licensed for use in children aged 6 years and older in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) where there has been an insufficient response to other DMARDs including methotrexate.

The safety and efficacy of Orencia have not been evaluated in children under 6 years of age and, therefore, it is not licensed in this age range.

View Orencia drug record

Further information: BMS

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.